AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05615818
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose: 1000 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
Trial: NCT04251182
Drug: 30 mg T3D-959
RxNorm normalized name: Reovirus type 3 (strain dearing) (t3d) (mammalian orthoreovirus 3)
DrugBank: Pelareorep (DB17284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily in the morning
Trial: NCT04251182
Drug: 45 mg T3D-959
RxNorm normalized name: Reovirus type 3 (strain dearing) (t3d) (mammalian orthoreovirus 3)
DrugBank: Pelareorep (DB17284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily in the morning
Trial: NCT04974398
Drug: Penpulimab
RxNorm normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A: Penpulimab (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin 80 mg/m2, administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine 1000 mg/ m2, administered on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), 3 weeks (21 days) per treatment cycle (Q3W), and then followed by penpulimab monotherapy as maintenance treatment, Q3W.
Trial: NCT04606316
Drug: Nivolumab-Placebo
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
Trial: NCT04606316
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given as intravenous (IV) infusion into a vein.
Trial: NCT04606316
Drug: Ipilimumab-Placebo
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
Trial: NCT04606316
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given as intravenous (IV) infusion into a vein.
Trial: NCT05605899
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05605899
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT05605899
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously
Trial: NCT05605899
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05605899
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06561958
Drug: REKOVELLE
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Individualised dosing regiment of REKOVELLE in routine clinical practice.
Trial: NCT06779396
Drug: The triamcinolone acetonide plus ropivacaine group
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The solution prepared comprised a mixture of 20mL of 0.2% ropivacaine(40mg) with 4 mg of triamcinolone acetonide. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
Trial: NCT06779396
Drug: The ropivacaine group
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The local infiltration solution containing 20mg of 1% ropivacaine. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
Trial: NCT04799015
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 10mg IV
Trial: NCT04799015
Drug: Metoclopramide 10mg
RxNorm normalized name: METOCLOPRAMIDE 10MG ORAL DISINTEGRAT TAB
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10mg IV
Trial: NCT04455750
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04455750
Drug: Rucaparib camsylate
RxNorm normalized name: Rucaparib camsylate
DrugBank: Rucaparib (DB12332)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT04455750
Drug: Leuprolide Acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IM
Trial: NCT04455750
Drug: Goserelin Acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT04455750
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given SC
Trial: NCT06207877
Drug: Cagrilintide
RxNorm normalized name: Cagrilintide
DrugBank: Cagrilintide (DB18887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cagrilintide will be administered subcutaneously.
Trial: NCT06207877
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide will be administered subcutaneously.
Trial: NCT00000862
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06667726
Drug: Fluorodopa F 18
RxNorm normalized name: FLUORODOPA F-18
DrugBank: Fluorodopa (18F) (DB13848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05775094
Drug: Romosozumab
RxNorm normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romosozumab will be administered 210 mg SC as two 105 mg prefilled syringes once every 4 weeks x 12 months. No dose adjustments for romosozumab will be permitted. All efforts will be made to administer romosozumab within the defined study visit windows (+/- 14 days).
Trial: NCT05917509
Drug: Cabotegravir (CAB) LA
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAB LA will be administered as a gluteal intramuscular injection once every 2 months in combination with RPV LA.
Trial: NCT05917509
Drug: Rilpivirine (RPV) LA
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RPV LA will be administered as a gluteal intramuscular injection once every 2 months in combination with CAB LA.
Trial: NCT02095847
Drug: Proflavine
RxNorm normalized name: proflavine
DrugBank: Proflavine (DB01123)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After hysteroscopy with HRME camera, uterine cavity infused with 10 mL of Proflavine.
Trial: NCT06205485
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m2 or 130 mg/m2 on day 1
Trial: NCT06667973
Drug: Gilteritinib
RxNorm normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Gilteritinib fumarate is an oral, selective FLT3 and AXL inhibitor. It is a type 1 inhibitor, active against both the FLT3-ITD and FLT3-TKD mutations. Gilteritinib inhibits FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y, and it induces apoptosis in leukemic cells expressing FLT3-ITD.~Gilteritinib is approved for the treatment of relpased/refractory FLT3-mutated AML after the successfull ADMIRAL trial. In the present study Gilteritinib (120 mg/die) in combination with FLAI will be tested as induction therapy in newly-diagnosed patients.
Trial: NCT05546411
Drug: 5-Fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion
Trial: NCT05546411
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion
Trial: NCT05546411
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of the FOLFIRINOX drug combination, given by intravenous infusion
Trial: NCT05042635
Drug: Ixekizumab+Jueyin Granules
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times.
Trial: NCT05546411
Drug: NIS793
RxNorm normalized name: Anti-tgf-beta monoclonal antibody nis793
DrugBank: Nisevokitug (DB17561)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by intravenous infusion
Trial: NCT05042635
Drug: Ixekizumab+Jueyin placebo Granules
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin placebo Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times.
Trial: NCT05153772
Drug: AlphaMedix
RxNorm normalized name: Alphamedix
DrugBank: Dotamtate Pb-212 (DB17312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 212Pb-DOTAMTATE is a radiolabeled derivative of octreotide targeting somatostatin positive neuroendocrine tumors
Trial: NCT05816720
Drug: Lutetium-177 DOTATATE
RxNorm normalized name: Lutetium-177
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT05934448
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab via iv, dosage and timing per protocol
Trial: NCT05934448
Drug: Lymphodepletion Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will undergo lymphodepleting chemotherapy (fludarabine, cyclophosphamide) for CAR T-cell therapy as per SOC
Trial: NCT05934448
Drug: Chimeric Antigen Receptor (CAR) Therapy Infusion
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 0 in the hospital and will remain in the inpatient setting for observation for a minimum of 7 days or until CAR T-cell toxicities resolve to grade 1 or better. The choice of CAR-T product will be left to the discretion of the treating investigator.
Trial: NCT03559673
Drug: Lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will start on the individual Lacosamide (LCM) dose that they had reached at the completion of the previous monotherapy study. LCM will be administered orally twice daily in 2 divided doses.
Trial: NCT06584929
Drug: Nicoderm CQ nicotine patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two week supply provided to participants on study.
Trial: NCT06584929
Drug: Nicorette Nicotine Lozenges
RxNorm normalized name: nicotine Oral Lozenge [Nicorette]
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two week supply provided to participants on study.
Trial: NCT05335070
Drug: Temporo-masseteric Nerve Block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following lower third molar extraction under intravenous sedation, the patient will receive the TMNB local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine on the side/s of the lower wisdom molar (third molar) extraction/s
Trial: NCT04501614
Drug: Ponatinib
RxNorm normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ponatinib tablets.
Trial: NCT06483100
Drug: Elrantamab
RxNorm normalized name: elranatamab
DrugBank: Elranatamab (DB15395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Elranatamab will be dosed in 28-day cycles as follows:~* C1D1: 12 mg SC priming dose~* C1D4: 32 mg SC priming dose~* C1D8, C1D15, C1D22: 76 mg SC~* Cycle 2 and all subsequent cycles: 76 mg SC on D1 and D15
Trial: NCT06283589
Drug: INZ-701
RxNorm normalized name: INZ-701
DrugBank: INZ-701 (DB17629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
Trial: NCT05009069
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weeks 8, 11 and 14: Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle for 3 cycles.
Trial: NCT05009069
Drug: Tiragolumab
RxNorm normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weeks 8, 11 and 14: Tiragolumab 600 mg IV on Day 1 of each 21-day cycle for 3 cycles.
Trial: NCT04697511
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive single oral dose of midazolam on Days 1, 3 and 13 under fed conditions.
Trial: NCT04697511
Drug: M2951
RxNorm normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive multiple oral doses (twice daily) of M2951 on Day 3 to Day 13 under fed conditions.
Trial: NCT00050271
Drug: Acetyl-L-carnitine
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05183035
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT05183035
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous (IV) infusion
Trial: NCT05183035
Drug: Gemtuzumab Ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT05183035
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) infusion or subcutaneous injection
Trial: NCT05183035
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orally via tablet or powder suspension
Trial: NCT05896293
Drug: kisspeptin 112-121
RxNorm normalized name: Kisspeptin
DrugBank: Kisspeptin (DB19112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)
Trial: NCT05896293
Drug: leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single SC bolus
Trial: NCT05482542
Drug: Cyclophosphamide/Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cyclophosphamide/Rituximab
Trial: NCT04640025
Drug: itacitinib
RxNorm normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will self-administer itacitinib orally using intact tablets with water and without regard to food.
Trial: NCT05509777
Drug: Mirikizumab
RxNorm normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV or SC
Trial: NCT04666038
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Pirtobrutinib
Trial: NCT04666038
Drug: Idelalisib
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral
Trial: NCT04666038
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT04666038
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV
Trial: NCT06054776
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05166577
Drug: Nanatinostat
RxNorm normalized name: Nanatinostat
DrugBank: Nanatinostat (DB15419)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1b: Nanatinostat dose escalation starting at 20 mg orally daily, 4 days per week, then Phase 2: Nanatinostat at the confirmed recommended Phase 2 dose
Trial: NCT05166577
Drug: Valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase 1b: Valganciclovir starting at 900 mg orally daily, then Phase 2: Valganciclovir at the confirmed recommended Phase 2 dose
Trial: NCT05166577
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase 2: Pembrolizumab (anti-PD-1) dosed at 200 mg intravenous (IV) every 3 weeks
Trial: NCT06437080
Drug: Ferric Carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 03 doses (50 mg iron/mL) per month for 03 months. This is assigned to Group B.
Trial: NCT06572813
Drug: Bortezomib Injection
RxNorm normalized name: bortezomib Injection
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib Injection, a kind of chemotherapy drug
Trial: NCT06572813
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 antibody
Trial: NCT04686305
Drug: T-DXd
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-DXd: administered as an IV infusion
Trial: NCT04686305
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin: administered as an IV infusion
Trial: NCT04686305
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin: administered as an IV infusion
Trial: NCT04686305
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed: administered as an IV infusion (drug not used)
Trial: NCT04686305
Drug: Volrustomig
RxNorm normalized name: Volrustomig
DrugBank: Volrustomig (DB18893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volrustomig: administered as an IV infusion
Trial: NCT04889183
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be treated for 24 weeks with semaglutide 3.0 mlg/ml s.c. once weekly. The starting dose of semaglutide will be 0.24 mg per week subcutaneous injection with increasing doses at 4, 8, 12, and 16 weeks to 0.5, 1,0, 1.7 and 2.4 mg.
Trial: NCT04686305
Drug: Rilvegostomig
RxNorm normalized name: Rilvegostomig
DrugBank: Rilvegostomig (DB18991)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilvegostomig: administered as an IV infusion
Trial: NCT06350773
Drug: tadalafil 20 mg then 40 mg if tolerated
RxNorm normalized name: tadalafil 40 MG
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive tadalafil for 12 week follow up period, in addition to the conventional anti failure therapy.
Trial: NCT06219317
Drug: Cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab is provided in a 10 ml glass vial
Trial: NCT03941860
Drug: Ixazomib Citrate
RxNorm normalized name: Ixazomib citrate
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03941860
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06133972
Drug: Ianalumab
RxNorm normalized name: Ianalumab
DrugBank: Ianalumab (DB16666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ianalumab s.c. monthly Ianalumab s.c. quarterly
Trial: NCT06497075
Drug: Albendazole 400mg
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of Albendazole 400mg tablet
Trial: NCT06497075
Drug: Ivermectin 3 MG
RxNorm normalized name: ivermectin 3 MG
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic ivermectin 3mg tablets given as a single oral dose of 200ug/kg using a dose-pole (height categories: 90-119 cm: 1 tablet , 120-140 cm: 2 tablets, 141-158 cm: 3 tablets or \> 158 cm: 4 tablets)